- Home
- SAGE
as 12-20-2024 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 462.2M | IPO Year: | 2014 |
| Target Price: | $11.53 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.62 - $28.26 | Next Earning Date: | 02-12-2025 |
| Revenue: | $106,399,000 | Revenue Growth: | 837.60% |
| Revenue Growth (this year): | -50.07% | Revenue Growth (next year): | 122.78% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
Sage Therapeutics price target lowered to $6 from $10 at Stifel
Business Wire
a month ago
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
TipRanks
a month ago
Sage Therapeutics price target lowered to $4 from $7 at BofA
MT Newswires
a month ago
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
Zacks
a month ago
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Clinical Trials Arena
a month ago
Sage ends dalzanemdor development following Phase II trial failure
Zacks
a month ago
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Benzinga
a month ago
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.